A detailed history of Jacob Asset Management Of New York LLC transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Jacob Asset Management Of New York LLC holds 7,677 shares of ARCT stock, worth $130,278. This represents 0.28% of its overall portfolio holdings.

Number of Shares
7,677
Previous 10,077 23.82%
Holding current value
$130,278
Previous $289,000 32.18%
% of portfolio
0.28%
Previous 0.33%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 01, 2023

SELL
$25.44 - $37.35 $61,056 - $89,640
-2,400 Reduced 23.82%
7,677 $196,000
Q2 2023

Aug 10, 2023

SELL
$23.94 - $32.36 $55,875 - $75,528
-2,334 Reduced 18.81%
10,077 $289,000
Q1 2023

May 11, 2023

SELL
$14.72 - $23.97 $31,059 - $50,576
-2,110 Reduced 14.53%
12,411 $297,000
Q4 2022

Feb 14, 2023

SELL
$14.14 - $23.06 $90,425 - $147,468
-6,395 Reduced 30.57%
14,521 $246,000
Q3 2022

Nov 10, 2022

BUY
$13.05 - $22.13 $535 - $907
41 Added 0.2%
20,916 $310,000
Q2 2022

Aug 11, 2022

SELL
$12.26 - $31.17 $49,530 - $125,926
-4,040 Reduced 16.22%
20,875 $329,000
Q1 2022

May 12, 2022

SELL
$17.64 - $39.57 $95,361 - $213,915
-5,406 Reduced 17.83%
24,915 $672,000
Q4 2021

Feb 09, 2022

SELL
$34.2 - $47.56 $883,522 - $1.23 Million
-25,834 Reduced 46.0%
30,321 $1.12 Million
Q3 2021

Nov 12, 2021

BUY
$27.88 - $58.25 $143,721 - $300,278
5,155 Added 10.11%
56,155 $2.68 Million
Q2 2021

Oct 04, 2021

BUY
$25.79 - $42.11 $670,540 - $1.09 Million
26,000 Added 104.0%
51,000 $1.73 Million
Q1 2021

Oct 04, 2021

BUY
$38.75 - $86.92 $379,750 - $851,816
9,800 Added 64.47%
25,000 $1.03 Million
Q4 2020

Oct 04, 2021

BUY
$34.61 - $123.66 $526,072 - $1.88 Million
15,200 New
15,200 $659,000

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $451M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Jacob Asset Management Of New York LLC Portfolio

Follow Jacob Asset Management Of New York LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacob Asset Management Of New York LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jacob Asset Management Of New York LLC with notifications on news.